Shares of Nectar Lifesciences Limited rose by 4.98% to ₹35.60 on Thursday following the company’s stellar financial performance for Q3 FY25. The company posted a 400% year-on-year (YoY) increase in profit after tax (PAT) at ₹78.40 million, compared to ₹15.67 million in Q3 FY24.
The revenue from operations for the quarter stood at ₹4,543.34 million, reflecting a slight increase from ₹4,521.65 million in the previous year. However, the company’s profitability was driven by improved EBITDA, which grew 6.1% YoY to ₹452.83 million, with margins expanding to 9.97%.
This impressive growth was attributed to higher-margin API exports, operational efficiencies, and cost optimization measures. Nectar Lifesciences’ management has laid out an optimistic outlook, targeting sustained growth through strategic expansions and debt reduction by FY26.
The stock movement highlights strong investor confidence, reflecting optimism about the company’s long-term profitability and strategic growth plans.
Disclaimer: The information provided is for informational purposes only and should not be considered financial advice. Please consult financial experts before making any investment decisions.